Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression

@article{Ware2010RapidlyAR,
  title={Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression},
  author={K. Ware and Marianne E. Marshall and L. R. Heasley and L. Marek and T. K. Hinz and Paula Hercule and B. Helfrich and R. Doebele and L. Heasley},
  journal={PLoS ONE},
  year={2010},
  volume={5}
}
Despite initial and sometimes dramatic responses of specific NSCLC tumors to EGFR TKIs, nearly all will develop resistance and relapse. Gene expression analysis of NSCLC cell lines treated with the EGFR TKI, gefitinib, revealed increased levels of FGFR2 and FGFR3 mRNA. Analysis of gefitinib action on a larger panel of NSCLC cell lines verified that FGFR2 and FGFR3 expression is increased at the mRNA and protein level in NSCLC cell lines in which the EGFR is dominant for growth signaling, but… Expand
Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
Resistance to epidermal growth factor receptor-targeted therapy.
  • F. Morgillo, Ho-Yyoung Lee
  • Biology, Medicine
  • Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • 2005
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.
Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines
...
1
2
3
4
...